Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational cell therapy consists of allogeneic umbilical cord blood-derived mesenchymal stromal stem cells (UCB-MSCs), developed by the University Medical Centre Ljubljana in collaboration with the Slovenian Institute for Transfusion Medicine. It is specifically designed for the treatment of end-stage knee osteoarthritis (Kellgren-Lawrence grade 4). The therapy is administered via intra-articular injection and functions by leveraging the regenerative and immunomodulatory properties of MSCs to promote cartilage repair and reduce synovial inflammation. Clinical evaluation is focused on understanding the mechanisms of action through biomarker analysis and patient-reported outcomes in individuals scheduled for total knee arthroplasty.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord blood-derived mesenchymal stromal stem cells (University Medical Centre Ljubljana).